Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Preparing for the NASH Epidemic: A Call to Action
Fasiha Kanwal, Jay H. Shubrook, Zobair M. Younossi, et al.
Diabetes Care (2021) Vol. 44, Iss. 9, pp. 2162-2172
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Kenneth Cusi, Scott Isaacs, Diana Barb, et al.
Endocrine Practice (2022) Vol. 28, Iss. 5, pp. 528-562
Open Access | Times Cited: 655
A global view of the interplay between non-alcoholic fatty liver disease and diabetes
Norbert Stefan, Kenneth Cusi
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 4, pp. 284-296
Closed Access | Times Cited: 402
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. s49-s67.2
Open Access | Times Cited: 154
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S52-S76
Open Access | Times Cited: 75
Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care
Juan Patricio Nogueira, Kenneth Cusi
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 20-28
Open Access | Times Cited: 46
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
Idoia Genua, Kenneth Cusi
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 48-58
Open Access | Times Cited: 29
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2025
Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, et al.
Diabetes Care (2024) Vol. 48, Iss. Supplement_1, pp. S59-S85
Closed Access | Times Cited: 18
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2022

Diabetes Care (2021) Vol. 45, Iss. Supplement_1, pp. S46-S59
Open Access | Times Cited: 72
Growth Hormone and Insulin-Like Growth Factor 1 Regulation of Nonalcoholic Fatty Liver Disease
Laura E. Dichtel, José Córdoba‐Chacón, Rhonda D. Kineman
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 107, Iss. 7, pp. 1812-1824
Open Access | Times Cited: 52
Diabetes and cirrhosis: Current concepts on diagnosis and management
Laurent Castéra, Kenneth Cusi
Hepatology (2023) Vol. 77, Iss. 6, pp. 2128-2146
Closed Access | Times Cited: 38
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)
Mazen Noureddin, Emily Truong, Rebeca Mayo, et al.
Hepatology (2023) Vol. 79, Iss. 1, pp. 135-148
Open Access | Times Cited: 36
Recent guidelines for Non-Alcoholic Fatty Liver disease (NAFLD)/ Fatty Liver Disease (FLD): Are they already outdated and in need of supplementation?
Laura Valenzuela‐Vallejo, Valentina Guatibonza-García, Christos S. Mantzoros
Metabolism (2022) Vol. 136, pp. 155248-155248
Closed Access | Times Cited: 32
Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients With Type 2 Diabetes and NAFLD
Srilaxmi Kalavalapalli, Eddison Godinez Leiva, Romina Lomonaco, et al.
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 108, Iss. 5, pp. 1192-1201
Open Access | Times Cited: 31
Non-invasive tools for liver steatosis and steatohepatitis predict incidence of diabetes, cardiovascular disease and mortality 20 years later: The ATTICA cohort study (2002–2022)
Matina Kouvari, Christina Chrysohoou, Evangelia Damigou, et al.
Clinical Nutrition (2024) Vol. 43, Iss. 3, pp. 900-908
Closed Access | Times Cited: 7
Lower risks of cirrhosis and hepatocellular carcinoma with GLP‐1RAs in type 2 diabetes: A nationwide cohort study using target trial emulation framework
Chun‐Ting Yang, Wenyu Yao, Chen‐Yi Yang, et al.
Journal of Internal Medicine (2023) Vol. 295, Iss. 3, pp. 357-368
Closed Access | Times Cited: 14
Making Sense of the Nonalcoholic Fatty Liver Disease Clinical Practice Guidelines: What Clinicians Need to Know
Kenneth Cusi, Jeff Budd, Eric L. Johnson, et al.
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 29-38
Open Access | Times Cited: 5
Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes
Erminia Lembo, Maria Francesca Russo, Ornella Verrastro, et al.
Diabetes & Metabolism (2022) Vol. 48, Iss. 5, pp. 101363-101363
Closed Access | Times Cited: 15
Racial Disparities in Evidence-Based Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes
Anastasia‐Stefania Alexopoulos, Alice Parish, Maren K. Olsen, et al.
Endocrine Practice (2024) Vol. 30, Iss. 7, pp. 663-669
Closed Access | Times Cited: 3
The diagnosis and management of nonalcoholic fatty liver disease: A patient‐friendly summary of the 2018 AASLD guidelines
Ranjeeta Bahirwani, Connor Griffin
Clinical Liver Disease (2022) Vol. 19, Iss. 6, pp. 222-226
Open Access | Times Cited: 13
Statin prescriptions and progression of advanced fibrosis risk in primary care patients with MASLD
Andrew D. Schreiner, Jingwen Zhang, Chelsey A. Petz, et al.
BMJ Open Gastroenterology (2024) Vol. 11, Iss. 1, pp. e001404-e001404
Open Access | Times Cited: 2
Approach to the Patient With Nonalcoholic Fatty Liver Disease
Renata Belfort‐DeAguiar, Romina Lomonaco, Kenneth Cusi
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 108, Iss. 2, pp. 483-495
Closed Access | Times Cited: 10
Indices of hepatic steatosis and fibrosis in prediabetes and association with diabetes development in the vitamin D and type 2 diabetes study
Karen D. Corbin, Anastassios G. Pittas, Cyrus Desouza, et al.
Journal of Diabetes and its Complications (2023) Vol. 37, Iss. 6, pp. 108475-108475
Closed Access | Times Cited: 5
A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China: a cross-sectional study
Qiling Liu, Gang Zhao, Qian Li, et al.
BMC Gastroenterology (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 9
Objective measures of cardiometabolic risk and advanced fibrosis risk progression in primary care patients with metabolic dysfunction-associated steatotic liver disease.
Andrew D. Schreiner, Jingwen Zhang, William P. Moran, et al.
Endocrine Practice (2024) Vol. 30, Iss. 11, pp. 1015-1022
Closed Access | Times Cited: 1
Smoking, all-cause, and cause-specific mortality in individuals with diabetes in Mexico: an analysis of the Mexico city prospective study
Daniel Ramírez‐García, Carlos A. Fermín‐Martínez, Paulina Sánchez-Castro, et al.
BMC Public Health (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top